ASN002 is an investigational drug.
There have been 7 clinical trials for ASN002.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 29th 2018.
The most common disease conditions in clinical trials are Dermatitis, Eczema, and Dermatitis, Atopic. The leading clinical trial sponsors are Asana BioSciences and [disabled in preview].
There are five US patents protecting this investigational drug and thirty international patents.